Bartlett & Co’s Denali Therapeutics DNLI Stock Holding History

Bartlett & Co’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$33K	Sell	1,500 -23,300	-94%	-$461K	﹤0.01%	775
2023 Q3	$512K	Buy	24,800 +3,260	+15%	+$82.7K	0.01%	331
2023 Q2	$636K	Hold	21,540	–	–	0.01%	310
2023 Q1	$496K	Buy	21,540 +760	+4%	+$20.9K	0.01%	292
2022 Q4	$578K	Hold	20,780	–	–	0.01%	274
2022 Q3	$638K	Buy	20,780 +2,269	+12%	+$73.8K	0.01%	250
2022 Q2	$545K	Buy	18,511 +1	+0%	+$26	0.01%	276
2022 Q1	$595K	Buy	18,510 +1,567	+9%	+$53.9K	0.01%	279
2021 Q4	$756K	Buy	16,943 +15,443	+1,030%	+$732K	0.01%	250
2021 Q3	$76K	Hold	1,500	–	–	﹤0.01%	453
2021 Q2	$118K	Hold	1,500	–	–	﹤0.01%	390
2021 Q1	$86K	Sell	1,500 -500	-25%	-$33.5K	﹤0.01%	445
2020 Q4	$168K	Buy	+2,000	New	+$121K	﹤0.01%	342

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bartlett & Co's DNLI Position: Q4 2023 in Review

Bartlett & Co reduced its Denali Therapeutics (DNLI) stake by 94% in Q4 2023, selling an estimated $461K and leaving 1,500 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #775.

Bartlett & Co first reported a position in DNLI in Q4 2020 and has held it in 13 quarters since. The position peaked at $756K in Q4 2021. 209 funds tracked by Wall St. Rank hold DNLI as of Q4 2023.

Bartlett & Co held 1,500 shares of Denali Therapeutics worth $33K as of Q4 2023.
Bartlett & Co sold 23,300 Denali Therapeutics shares in Q4 2023, an estimated $461K.
Denali Therapeutics made up ﹤0.01% of Bartlett & Co's portfolio in Q4 2023, its #775 holding.
Bartlett & Co first reported a position in Denali Therapeutics in Q4 2020 and has held it in 13 quarters since.
Bartlett & Co's Denali Therapeutics position peaked at $756K in Q4 2021.
209 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2023.

Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.